Exonhit loss and reduced its costs by 2011, as the decline
The title Exonhit significantly lower Thursday at the Paris Bourse after the publication of 2011 results considered very encouraging for the future of the biotechnology company, according to stakeholders.
For the past year, Exonhit reduced its loss to 7.1 million euros, against a loss of 7.7 million in 2010, and indicated that on 31 December 2011, his strated ; Flow was $ 12.9 million, giving it about 24 months of cash.
She also announced today have repaid all its long-term debt.
Turnover dropped to 5 million euros last year, against 8.4 million a year earlier.
The company claims to have achieved savings in 2011 of two million euros in a full year after abandoning a planned acquisition and cut expenses on clinical Aclarus DX, the blood test of Alzheimer's disease.
Present equally in the market for drugs for neurodegenerative diseases and the diagnosis, Exonhit gives no numerical targets for 2012 merely say "more than ever" confident in achieving its prospects.
"The year 2012 will Exonhit to that of expanding our portfolio of diagnostic products, its own or in collaboration, while maintaining a solid financial structure," said the pre Chairman of the Executive Loïc Maurel, said in the statement of results.
At 11:10, the action Exonhit lost 9.36% to 1.84 euros in large volumes, showing a market capitalization of 62.78 million euros. At this price level, the title was up 73.6% since the beginning of the year, after a loss of 48.29% last year.
At Bryan Garnier, Sebastien Malafosse the analyst points out that the market "expects a start-up Exonhit as it invests in its future development rather than focus on reducing of its cost structure ".
The views of the steps taken in 2011, he continues, "the road is still long for Exonhit and maturity of 24 months of cash could happen quickly."
With other analysts, however, it notes that the action has Exonhit, like those of other biotechs, gained much ground in recent sessions, so the decline of this morning can also be explained by profit taking.